Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

  • High-risk acute leukemia, including any of the following:

    • Refractory acute leukemia
    • Acute leukemia beyond first remission
    • Acute leukemia in first remission with poor prognostic features (e.g., chromosomal changes suggesting poor prognosis)
  • Chronic myelogenous leukemia in second chronic, accelerated, or blastic phase
  • Severe aplastic anemia that is not responsive to immunosuppressive therapy

  • Myelodysplastic syndromes, including any of the following:

    • Refractory anemia (RA) or RA with ringed sideroblasts with severe cytopenia
    • RA with excess blasts (RAEB)
    • RAEB in transformation
    • Chronic myelomonocytic leukemia
  • Refractory or relapsed non-Hodgkin or Hodgkin lymphoma
  • Multiple myeloma

  • Biopsy proven measurable solid tumor meeting 1 of the following criteria:

    • Recurrent disease after primary treatment and deemed incurable to standard treatment
    • Metastatic disease for which no known standard therapy that is potentially curative or definitely capable of extending life expectancy exists
• Must have a related HLA-haploidentical mismatched (3/6 or fewer loci) donor available

PATIENT CHARACTERISTICS:

• Karnofsky performance status 70-100%
• Bilirubin < 2.0 mg/dL
• AST < 3 times upper limit of normal
• Creatinine < 2.0 mg/dL
• Ejection fraction > 40% by MUGA

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics